

PE anti-mouse CD19 Antibody

Catalog# / Size	115507 / 50 µg 115508 / 200 µg
Clone	6D5
Regulatory Status	RUO
Other Names	B4
Isotype	Rat IgG2a, κ
Description	CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse CD19-expressing K562 human erythroleukemia cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunofluorescence ⁷ .
Application References	<ol style="list-style-type: none"> Shoham T, <i>et al.</i> 2003. <i>J. Immunol.</i> 171:4062. (FC) Goodyear CS, <i>et al.</i> 2004. <i>J. Immunol.</i> 172:2870. (FC) Kamimura D, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:306. (FC) Andoniou CE, <i>et al.</i> 2005. <i>Nat. Immunol.</i> 6:1011. (FC) Lawson BR, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:5366. (FC) Phan TG, <i>et al.</i> 2007. <i>Nat. Immunol.</i> 8:992. (FC) Hayashida K, <i>et al.</i> 2008. <i>J. Biol. Chem.</i> 283:19895. (IF) PubMed Charles N, <i>et al.</i> 2010. <i>Nat. Med.</i> 16:701. (FC) PubMed Bankoti J, <i>et al.</i> 2010. <i>Toxicol. Sci.</i> 115:422. (FC) PubMed Stadnisky MD, <i>et al.</i> 2011. <i>Blood.</i> 117:5133. (FC) PubMed Perlot T, <i>et al.</i> 2012. <i>J. Immunol.</i> 188:1201. (FC) PubMed Olive V, <i>et al.</i> 2013. <i>Elife.</i> 2:822. PubMed Miyai T, <i>et al.</i> 2014. <i>PNAS.</i> 111:11780. PubMed
Product Citations	<ol style="list-style-type: none"> Jayachandran R, <i>et al.</i> 2019. <i>Immunity.</i> 50:152. PubMed Ying W, <i>et al.</i> 2019. <i>Cell Metab.</i> 29:457. PubMed

3. Wang X, *et al.* 2019. *Cell Res.* 29:787. [PubMed](#)
4. Grigsby SM, *et al.* 2021. *Cancers (Basel)*. 13:. [PubMed](#)
5. Wang Q, *et al.* 2020. *Radiat Environ Biophys.* 59:89. [PubMed](#)
6. Goncalves S, *et al.* 2021. *Cell Reports.* 34(11):108860. [PubMed](#)
7. Murphy C, *et al.* 2012. *Infect Immun.* 80:2712. [PubMed](#)
8. Baryawno N *et al.* 2019. *Cell.* 177(7):1915-1932. [PubMed](#)
9. Gawish R, *et al.* 2022. *Elife.* 11:. [PubMed](#)
10. Fan L, *et al.* 2021. *Cancers (Basel)*. 13:. [PubMed](#)
11. Fistonich C, *et al.* 2018. *J Exp Med.* 215:2586. [PubMed](#)
12. Silver AC, *et al.* 2018. *Heliyon.* 4:e00579. [PubMed](#)
13. Yang C, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
14. Acharya N, *et al.* 2020. *Immunity.* 53(3):658-671.e6. [PubMed](#)
15. Culina S, *et al.* 2014. *PLoS One.* 9:88365. [PubMed](#)
16. Hiraishi Y, *et al.* 2018. *Sci Rep.* 8:18052. [PubMed](#)
17. Bowers E, *et al.* 2018. *Nat Med.* 24:95. [PubMed](#)
18. Shu T, *et al.* 2022. *Eur Respir J.* Online ahead of print. [PubMed](#)
19. del Rio ML, *et al.* 2021. *Transl Res.* Online ahead of print.. [PubMed](#)
20. Molina-Sanchez P, *et al.* 2020. *Gastroenterology.* 2203:159. [PubMed](#)
21. Kosack L, *et al.* 2017. *Sci Rep.* 7:11289. [PubMed](#)
22. Zhang X, *et al.* 2020. *J Immunol.* 205:1743. [PubMed](#)
23. Yamaguchi T, *et al.* 2010. *Genes Dev.* 24:455. [PubMed](#)
24. Vannini N, *et al.* 2019. *Cell Stem Cell.* 24:405. [PubMed](#)
25. Stutchfield B, *et al.* 2015. *Gastroenterology.* 149: 1896-1909.e14. [PubMed](#)
26. Kurkewich J, *et al.* 2016. *PLoS One.* 11: 0161468. [PubMed](#)
27. Hu EY, *et al.* 2021. *Blood Adv.* 5:3152. [PubMed](#)
28. Wang F, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 13:257. [PubMed](#)
29. Benet Z, *et al.* 2021. *Cell Reports.* 34(6):108733. [PubMed](#)
30. Tong Q, *et al.* 2022. *FEBS Open Bio.* 12:1542. [PubMed](#)
31. McAlpine CS, *et al.* 2021. *Nature.* 595:701. [PubMed](#)
32. Ruer-Laventie J, *et al.* 2020. *Bio Protoc.* e3531:10. [PubMed](#)
33. Onder L *et al.* 2017. *Immunity.* 47(1):80-92. [PubMed](#)
34. Ghandhi SA, *et al.* 2022. *Sci Rep.* 12:14124. [PubMed](#)
35. Yang H, *et al.* 2022. *Nutrients.* 14:. [PubMed](#)
36. Knizkova D, *et al.* 2022. *Nat Immunol.* 23:1644. [PubMed](#)
37. Osaka M, *et al.* 2016. *Sci Rep.* 6:21391. [PubMed](#)
38. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
39. Chauveau A, *et al.* 2020. *Immunity.* 52:794. [PubMed](#)
40. Zhang H, *et al.* 2019. *Mol Cell.* 76:110. [PubMed](#)
41. Cho K, *et al.* 2021. *iScience.* 24:103117. [PubMed](#)
42. Bourque J, *et al.* 2021. *Heliyon.* 7:e08311. [PubMed](#)
43. Ruiz-Manzano RA, *et al.* 2020. *Frontiers in Oncology.* 0.927777778. [PubMed](#)
44. Ghandhi SA, *et al.* 2019. *Sci Rep.* 9:19434. [PubMed](#)
45. Yu X, *et al.* 2019. *Nat Commun.* 10:574. [PubMed](#)
46. Kang X, *et al.* 2022. *J Immunol Res.* 2022:8118577. [PubMed](#)
47. Ding P, *et al.* 2022. *Bone Res.* 10:42. [PubMed](#)
48. Huang J, *et al.* 2014. *J Immunol.* 192:1972. [PubMed](#)
49. Cho S, *et al.* 2018. *Nat Commun.* 9:2757. [PubMed](#)
50. Yang BH, *et al.* 2020. *Cell Reports.* 27(12):3629-3645.e6.. [PubMed](#)
51. Souza SP, *et al.* 2021. *PLoS Pathog.* 17:e1010081. [PubMed](#)
52. Gamrekelashvili J, *et al.* 2021. *Bio Protoc.* 11:e4007. [PubMed](#)
53. Chen RJ, *et al.* 2022. *iScience.* 25:105595. [PubMed](#)
54. Yuan X, *et al.* 2017. *Elife.* 6:e29540. [PubMed](#)
55. Bitschar K, *et al.* 2019. *Nat Commun.* 10:2730. [PubMed](#)
56. Raoof R, *et al.* 2021. *J Neurosci.* 41:8249. [PubMed](#)
57. Mohammadi MR, *et al.* 2021. *Commun Biol.* 4:685. [PubMed](#)
58. Gorina R, *et al.* 2014. *J Immunol.* 192:324. [PubMed](#)
59. Muenchow L, *et al.* 2014. *Immunol Lett.* 160:113. [PubMed](#)
60. Winkler ES, *et al.* 2020. *Cell.* 182(4):901-918.e18. [PubMed](#)
61. Xu C, *et al.* 2020. *Immunity.* 53(2):417-428.e4. [PubMed](#)
62. Shu Z, *et al.* 2020. *Mar Drugs.* 18:00. [PubMed](#)
63. Ulrich V, *et al.* 2016. *EMBO Mol Med.* 8: 643 - 653. [PubMed](#)
64. McCauley ME, *et al.* 2020. *Nature.* 585(7823):96-101. [PubMed](#)
65. Georgiadou A, *et al.* 2022. *Elife.* 11:. [PubMed](#)
66. Xiao Y, *et al.* 2021. *Cell.* 184:6037. [PubMed](#)
67. Vijay R, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
68. Singhal P, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 122 - 127. [PubMed](#)
69. Takahashi T, *et al.* 2017. *J Exp Med.* 10.1084/jem.20160247. [PubMed](#)
70. Jaitin DA *et al.* 2016. *Cell.* 167(7):1883-1896. [PubMed](#)
71. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
72. Tsyklauri O, *et al.* 2021. *EMBO Rep.* 22:e50785. [PubMed](#)
73. Subramaniam N, *et al.* 2021. *Blood Adv.* 5:1259. [PubMed](#)
74. Aulova KS, *et al.* 2022. *Molecules.* 27:. [PubMed](#)
75. Martins R, *et al.* 2016. *Nat Immunol.* 17:1361-1372. [PubMed](#)
76. Jiang Y, *et al.* 2015. *MBio.* 6: e01426-15. [PubMed](#)
77. Aalipour A, *et al.* 2020. *Mol Ther Oncolytics.* 17:232. [PubMed](#)
78. Gundra UM, *et al.* 2017. *Nat Immunol.* 1.195833333. [PubMed](#)
79. Huppé CA, *et al.* 2018. *Mucosal Immunol.* 0.536111111. [PubMed](#)
80. Sheng D, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
81. Vijay R, *et al.* 2020. *Nat Immunol.* 21:790. [PubMed](#)
82. Schubert M, *et al.* 2021. *Cancers (Basel)*. 13:. [PubMed](#)

83. Vannini N, *et al.* 2016. *Nat Commun.* 7:13125. [PubMed](#)
84. Hall JA, *et al.* 2020. *Cell Metabolism.* 32(4):665-675.e6. [PubMed](#)
85. Heyde A, *et al.* 2021. *Cell.* 184(5):1348-1361.e22. [PubMed](#)
86. Wali S, *et al.* 2020. *Am J Respir Cell Mol Biol.* 758:63. [PubMed](#)
87. Syres K, *et al.* 2009. *Blood.* 114:2452. [PubMed](#)
88. Das A, *et al.* 2020. *J Bone Miner Res.* 36:199. [PubMed](#)
89. Kerdidani D, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
90. Gawish R, *et al.* 2022. *Elife.* 11:. [PubMed](#)
91. Yang H, *et al.* 2022. *Viruses.* 14:. [PubMed](#)
92. Wirasinha RC, *et al.* 2021. *J Exp Med.* 218: . [PubMed](#)

RRID AB_313642 (BioLegend Cat. No. 115507)
 AB_313643 (BioLegend Cat. No. 115508)

Antigen Details

Structure	Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution	Pro-B cells to mature B cells (during development), follicular dendritic cells
Function	Modulates B cell activation and differentiation
Ligand/Receptor	CD21, CD81, Leu-13
Cell Type	B cells, Dendritic cells
Biology Area	Costimulatory Molecules, Immunology
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Fearon DT. 1993. <i>Curr. Opin. Immunol.</i> 5:341. 2. Krop I, <i>et al.</i> 1996. <i>Eur. J. Immunol.</i> 26:238. 3. Krop I, <i>et al.</i> 1996. <i>J. Immunol.</i> 157:48. 4. Tedder TF, <i>et al.</i> 1994. <i>Immunol. Today</i> 15:437.
Gene ID	12478


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

APC anti-mouse CD19, Biotin anti-mouse CD19, FITC anti-mouse CD19, PE anti-mouse CD19, PE/Cyanine5 anti-mouse CD19, Purified anti-mouse CD19, PE/Cyanine7 anti-mouse CD19, Alexa Fluor® 488 anti-mouse CD19, Alexa Fluor® 647 anti-mouse CD19, Pacific Blue™ anti-mouse CD19, Alexa Fluor® 700 anti-mouse CD19, APC/Cyanine7 anti-mouse CD19, PerCP anti-mouse CD19, PerCP/Cyanine5.5 anti-mouse CD19, Alexa Fluor® 594 anti-mouse CD19, Brilliant Violet 421™ anti-mouse CD19, Brilliant Violet 570™ anti-mouse CD19, Brilliant Violet 605™ anti-mouse CD19, Brilliant Violet 650™ anti-mouse CD19, Brilliant Violet 785™ anti-mouse CD19, Brilliant Violet 510™ anti-mouse CD19, Purified anti-mouse CD19 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD19, Brilliant Violet 711™ anti-mouse CD19, APC/Fire™ 750 anti-mouse CD19, TotalSeq™-A0093 anti-mouse CD19, Brilliant Violet 750™ anti-mouse CD19, TotalSeq™-B0093 anti-mouse CD19, Spark Blue™ 550 anti-mouse CD19, Spark NIR™ 685 anti-mouse CD19, TotalSeq™-C0093 anti-mouse CD19, Ultra-LEAF™ Purified anti-mouse CD19, PE/Fire™ 640 anti-mouse CD19 Antibody, Spark YG™ 581 anti-mouse CD19, APC/Fire™ 810 anti-mouse CD19, Spark YG™ 570 anti-mouse CD19, Spark Blue™ 574 anti-mouse CD19 Antibody

Product Data



C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).



C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).

Data was acquired on the Moxi Flow, exported, and processed using FlowJo software.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587